"The
Report Refractory Acute Myeloid Leukemia Global Clinical Trials
Review, H2, 2016 provides information on pricing, market analysis,
shares, forecast, and company profiles for key industry participants.
- MarketResearchReports.biz"
GlobalData's
clinical trial report, Refractory
Acute Myeloid Leukemia
Global Clinical Trials Review, H2, 2016" provides an overview of
Refractory Acute Myeloid Leukemia clinical trials scenario. This
report provides top line data relating to the clinical trials on
Refractory Acute Myeloid Leukemia. Report includes an overview of
trial numbers and their average enrollment in top countries conducted
across the globe. The report offers coverage of disease clinical
trials by region, country (G7 & E7), phase, trial status, end
points status and sponsor type. Report also provides prominent drugs
for in-progress trials (based on number of ongoing trials).
GlobalData Clinical Trial Reports are generated using GlobalDatas
proprietary database - Pharma eTrack Clinical trials database.
Clinical trials are collated from 80+ different clinical trial
registries, conferences, journals, news etc across the globe.
Clinical trials database undergoes periodic update by dynamic
process.
The
report enhances the decision making capabilities and helps to create
an effective counter strategies to gain competitive advantage.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/816355
Scope
-
The report provides a snapshot of the global clinical trials
landscape
-
Report provides top level data related to the clinical trials by
Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor
Type and End point status
-
The report reviews top companies involved and enlists all trials
(Trial title, Phase, and Status) pertaining to the company
-
The report provides all the unaccomplished trials (Terminated,
Suspended and Withdrawn) with reason for unaccomplishment
-
The Report provides enrollment trends for the past five years
-
Report provides latest news for the past three months
Reasons
to buy
-
Assists in formulating key business strategies with regards to
investment
-
Helps in identifying prominent locations for conducting clinical
trials which saves time and cost
-
Provides top level analysis of Global Clinical Trials Market which
helps in identifying key business opportunities
-
Supports understanding of trials count and enrollment trends by
country in global therapeutics market
-
Aids in interpreting the success rates of clinical trials by
providing a comparative scenario of completed and uncompleted
(terminated, suspended or withdrawn) trials
-
Facilitates clinical trial assessment of the indication on a global,
regional and country level
Table
of Contents
Table
of Contents 2
List
of Tables 3
List
of Figures 4
Report
Guidance 5
Clinical
Trials by Region 6
Clinical
Trials and Average Enrollment by Country 7
Top
Five Countries Contributing to Clinical Trials in Asia-Pacific 10
Top
Five Countries Contributing to Clinical Trials in Europe 11
Top
Countries Contributing to Clinical Trials in North America 12
Top
Countries Contributing to Clinical Trials in Middle East and Africa
13
Top
Countries Contributing to Clinical Trials in Central and South
America 14
Clinical
Trials by G7 Countries: Proportion of Refractory Acute Myeloid
Leukemia to Oncology Clinical Trials 15
Clinical
Trials by Phase in G7 Countries 16
Clinical
Trials in G7 Countries by Trial Status 17
Clinical
Trials by E7 Countries: Proportion of Refractory Acute Myeloid
Leukemia to Oncology Clinical Trials 18
Clinical
Trials by Phase in E7 Countries 19
Clinical
Trials in E7 Countries by Trial Status 20
Clinical
Trials by Phase 21
In
Progress Trials by Phase 22
Clinical
Trials by Trial Status 23
Clinical
Trials by End Point Status 24
Subjects
Recruited Over a Period of Time 25
Clinical
Trials by Sponsor Type 26
Prominent
Sponsors 27
Top
Companies Participating in Refractory Acute Myeloid Leukemia
Therapeutics Clinical Trials 28
Prominent
Drugs 30
Latest
Clinical Trials News on Refractory Acute Myeloid Leukemia 31
Jul
20, 2016: Actinium Pharmaceuticals Highlights Successful Investigator
Meeting for Pivotal Phase 3 Iomab-B SIERRA Trial 31
Jul
06, 2016: Actinium Pharmaceuticals to Sponsor Investigator Meeting
for Pivotal Phase 3 SIERRA Trial for Iomab-B 32
Jun
29, 2016: Actinium Pharmaceuticals Initiates Pivotal Phase 3 SIERRA
Trial 33
Jun
13, 2016: Tolero Pharmaceuticals Presents Nonclinical Data
Demonstrating Alvocidib Provides Drug Combination Strategies Due to
the Targeting of MCL-1 34
Jun
09, 2016: Actinium Announces Strong Presence at Society of Nuclear
Medicine and Molecular Imaging Annual Meeting 34
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment